Artificial Intelligence
Global Molecular Diagnostics Industry Analysis (2020-2025) and the Impact of COVID-19
Dublin, Aug. 28, 2020 (GLOBE NEWSWIRE) — The “Molecular Diagnostics Markets in the COVID-19 Era (Markets for Molecular COVID-19 IVD Tests, Respiratory Tests, Blood Screening, Cancer Markers and Other IVD Tests)” report has been added to ResearchAndMarkets.com’s offering.
Now more than ever, molecular diagnostics are the most important part of in vitro diagnostics. The analyst has, for many years, estimated the size of and forecasted the growth of the worldwide market for molecular diagnostics in all major segments, and does so in this edition as a pandemic has reached developed markets including the United States.
2020 was set to be a year of growth and innovations in molecular diagnostics under any circumstances. New products, higher growth than other in vitro diagnostic categories, continued acceptance of next-generation sequencing methods were driving. Liquid biopsy technologies and the increased use of predictive genetic tests were and still are areas of anticipated revenue growth. The sudden onset of SARS-CoV-2 and the resulting disease COVID-19 put the world’s focus on molecular diagnostics in an unexpected way.
This will not be universally the case. In non-COVID-19 testing areas, such as cancer and inherited diseases, molecular diagnostics vendors need to continue to persuade. Here volumes may be reduced by social distancing measures. But they are expected to continue to make progress converting laboratory customers. New technologies such as molecular near-patient and next-generation sequencing are increasingly part of the mix. The report details these trends.
This report provides 2020 market sizing and expected growth to 2025 for the following segments:
- COVID-19 Molecular IVD Test Market (Full Year 2020 Projected and Market 2H 2020)
- COVID-19 Molecular IVD Test Market North America
- COVID-19 Molecular IVD Test Market Europe
- COVID-19 Molecular IVD Test Market Asia-Pacific
- COVID-19 Molecular IVD Test Market Rest of World
- Infectious Disease Markets, including:
- Hepatitis
- HIV
- Respiratory
- HAIs and Sepsis Tests
- TB
- Sexually Transmitted Diseases
- NAT Blood Testing
- Molecular Histology
- Molecular Cancer Testing
- Molecular Transplantation Testing
- Inherited Disease Testing
- NIPT
- Inherited
- Thrombophilia
- Pharmacogenomics
There has also been a huge influx of product introductions from small, obscure companies. These have mostly targeted the low end of the price range and often had poor performance, while a small number of high-end automated systems are mostly limited to certain segments of the market, such as independent reference laboratories and centralized hospital laboratories. Low-quality products from fly-by-night companies are the predictable result of the shortages and the relatively basic resources needed to produce mediocre antibody test kits with a low level of quality control. A few major companies are seeing the most test runs, particularly in the United States.
COVID-19 testing has also been a bit of a double-edged sword for labs generally, for in vitro diagnostics and for molecular tests. Boosting volumes in infectious disease have been notably paired with drops due to social distancing measures and hospital surgical postponements. What is the result? The report helps to sort out the array of news and reports about the current state of molecular diagnostics, reasonable global estimates for COVID, and the impact of COVID-19 on the rest of molecular testing.
The report covers the global markets. For All Markets, the analyst provides the following:
- Impacts of COVID-19 on Market Segments
- Regional Market Distribution
- Profiles of Top Companies
- Major Companies with COVID-19 Tests
- Other Companies with COVID-19 Tests
- HIV Products on the Market
- Transplantation Products on the Market
- The Increasing Role of Next-Generation Sequencing
- Trends – Lab Automation and Molecular Diagnostics
- Trends – CRISPR
- Trends – Artificial Intelligence
- Company Profiles
The analyst has monitored 2020 secondary sources, trade publications, medical journals, government websites and policy documents, as well as financial statements from vendors to assess the market impact of COVID-19. In addition, the analyst has been tracking lab volumes with a survey since mid-April, and the analyst U.S. MasterFile product was used to keep track of instrument trends.
Key Topics Covered
Chapter One: Executive Summary
- COVID-19 Testing
- Hundreds of Tests on The Market, U.S. Labs Settle on a Few
- Emerging Trends Influencing the Market Landscape
- Reimbursement Environment
- Regulatory Status of Laboratory Developed Tests (LDTs)
- The Global Molecular Diagnostics Market in the Era of COVID-19
- Next-Generation Sequencing on the Rise
- Molecular Diagnostics Markets
Chapter Two: COVID-19
- Hundreds of Tests on The Market, U.S. Labs Settle on a Few
- Regional Variance in Cases and Testing
- Other COVID-19 RT-PCR Tests
- Testing trends, recommendations, consensus taking shape
Chapter Three: Sequencing, CRISPR, Automation, and Other Trends
- Sequencing
- COVID and NGS
- Inherited Disease
- Companion Diagnostics
- Outlook For NGS
- Evolving Informatics Solutions in Clinical Sequencing
- Sample Preparation and Quality Control
- Lab Automation and Molecular Diagnostics
- CRISPR and Molecular Diagnostics
- CRISPR and COVID-19
- Microbiome and Molecular Diagnostics
- Artificial Intelligence
Chapter Four: Markets for Molecular Infectious Disease Diagnostics
- Global Market Overview
- Repiratory Diseases
- COVID-19 Impact
- Mycobacteria/Tuberculosis
- COVID-19 Impact
- Product Developments
- Hospital-Acquired Infections (HAIs)
- COVID-19 Impact
- COVID as a hospital infection?
- Product Developments
- Size and Growth of the Market
- Sexualty Transmitted Infections: CT/NG, Others
- COVID-19 Impact
- HPV
- Eliminating HPV Threat: Lancet Public Health Study
- COVID-19 Impact
- HPV Vaccine and Market Effects
- Product Developments
- Size and Growth of Market
- Hepatitis
- Hepatitis Types
- New HCV Screening Guidelines
- COVID-19 Impact
- Product Developments
- Tranisition to Molecular POC
- Size and Growth of the Market
- HIV
- New Guidelines
- COVID-19 Impact
- Product Developments
- Size and Growth of the Market
Chapter Five: Markets for Molecular Blood Screening Diagnostics
- COVID-19 Impact
- Other Trends
- Declining Blood Transfusions in Developed Markets
- Growing Demand in Developing Nations
- New Infectious Disease Threats and Assay Introductions
- Nucleic Acid Testing Markets for Blood Screening
- Size and Growth of the Market
Chapter Six: Markets for Molecular Histology and Cytology Diagnostics
- In Situ Hybridization (ISH)
- Histology Automation
- Prenatal Testing Moving from FISH to NIPT
- Size and Growth of the Market
Chapter Seven: Markets for Molecular Cancer Diagnostics
- COVID-19 Impact
- Other Trends
- Predictive Biomarker Tests for Identifying Drug-Gene Match
- Liquid Biopsy
- Relevant DNA/RNA Variants
- Lung Cancer Study Provides Justification for MDx
- Cancer Rates
- Product Developments
- Size and Growth of the Market
- U.S. Reimbursement Structure
- Cancer Molecular Diagnostics Markets, Europe
- Reimbursement Structure, Challenges and Recent Activity
- Cancer Molecular Diagnostics Markets, APAC
- Japan
- China
- Reimbursement Environment in India
- ASEAN
Chapter Eight: Markets for Molecular Transplant Diagnostics
- COVID-19 Impact
- Other Trends
- Role of NGS Increasing
- Competitive Situation in Transplantation Diagnostics
- Immucor
- Qiagen
- CareDX
- ThermoFisher
- GeneDX
- Omixon
- Biofortuna
- Size and Growth of the Molecular Transplant Diagnostics Market
Chapter Nine: Markets for Molecular Inherited Diseases Diagnostics
- COVID-19 Impact
- Trends in the Market
- Pilot Program Baby Bear in the United States
- China
- India
- Thrombophilia and Coagulation Markers
- Non-Invasive Prenatal Testing (NIPT)
- Product Developments
- Promising NIPT Studies
- Other Tests
- Autism
- Seizures
- Alzheimer’s Disease
- Cardiovascular Disease
- Psychiatric Disorders
- Size and Growth of the Market
Chapter Ten: Company Profiles
- 3B BlackBio Biotech India Ltd
- ARUP Laboratories
- Abbott Diagnostics
- Advanced Cell Diagnostics
- Agena Bioscience
- Agendia BV
- Agilent
- altona Diagnostics GmbH
- Amoy Diagnostics
- Amoy Dx
- Anitoa
- AnyGenes
- Applied DNA Sci
- Applied Spectral Imaging
- Asuragen
- BGI
- BGI Genomics Co. Ltd
- Beckman Coulter
- Becton, Dickinson & Co.
- Berry Genomics
- Bio-Rad
- BioCore Co., Ltd.
- BioGX
- BioMerieux
- Biocartis
- Biomeme
- Bioneer
- Bioperfectus Technologies Co. Ltd
- Bruker
- CTK Biotech
- Care DX
- Cepheid
- Chroma Code
- Coyote Bioscience
- Credo Dx BioMed
- DNA XPERTS
- Danaher
- DiaCarta, Inc.
- DiaSorin Molecular LLC
- Diagnostics for the Real World Ltd
- Dian Biotechnology Co., Ltd
- EasyDiagnosis Biomedicine Co., Ltd
- Eiken Chemical
- Enzo Biochem
- Eurobio
- Euroimmun US Inc.
- Fluidigm
- GenMark
- GenScript,
- Gencurix, Inc.
- GeneMatrix, Inc.
- Genesystems (Pall sub)
- Genetic PCR Signatures Limited
- Genomictree, Inc.,
- Genotypic Technology Pvt
- gerbion GmbH & Co.
- Gnomegen LLC
- Greiner Bio-One GmbH
- Grifols
- Haitai Biological Pharmaceutical Co., Ltd
- Hologic
- Illumina
- Immucor
- Leica Biosystems
- Maccura Biotechnology
- Medical & Biological Laboratories Co., Ltd
- Meridian Biosciences
- Mesa Biotech Inc.
- MobiDiag
- Molbio Dx
- Myriad Genetics
- Nanostring
- Neogenomics
- NeuromoDX
- Osang Healthcare
- Oxford Nanopore
- Perkin Elmer
- PlexBio Co., Ltd.
- PreciGenome LLC
- Prescient Medicine
- Primerdesign Ltd.
- Promega
- Promis
- Qiagen
- QuantuMDx
- Quidel
- Rheonix
- Rheonix, Inc.
- Roche
- Roche Molecular Systems, Inc. (RMS)
- Sansure Biotech, Inc.
- Seasun
- Seegene
- Seegene, Inc.
- Shahai GeneoDx Biotechnology Co., Ltd
- SolGent Co., Ltd
- Thermo
- Thermo Fisher Scientific, Inc.
- Vela
- Veracyte
- Veredus Labs
- Vircell, S.L.
- Wuxi Shenrui Bio-pharmaceuticals Co. Ltd
- Zymo Research
For more information about this report visit https://www.researchandmarkets.com/r/9eza8i
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Artificial Intelligence
Tencent Announces Winners of Flagship CarbonX Program to Combat Climate Change
SHENZHEN, China, May 23, 2024 /PRNewswire/ — Tencent (00700.HK) is awarding 13 exceptional teams that won the first phase of its groundbreaking CarbonX Program, which is aimed at boosting promising new climate technologies. The winners, which emerged from a pool of 30 finalists and more than 300 initial applications, will receive a total of around RMB 100 million (US$14 million) in financial support from Tencent. It showcases the company’s commitment to driving sustainable social innovations in the fight against climate change.
CarbonX was launched in March 2023 to advance the next generation of low-carbon technologies. Tencent has committed RMB 200 million (US$28 million) in catalytic funding over the next three years to innovative ideas that might otherwise languish or fail to gain traction.
CarbonX’s first phase focused on carbon capture, utilization, and storage (CCUS), as well as technology-based carbon removal. These solutions were chosen for their unique ability to curb emissions from hard-to-abate industries such as steel and cement, mitigate the continued reliance on fossil fuels, and reduce legacy emissions created from decades of industrialization.
Backed by Tencent’s mission of Tech for Good and an alliance of like-minded industry partners, CarbonX aims to help these cutting-edge technologies make the leap from the research or early startup stage to commercial scale. The ultimate goal is supporting them in making a significant impact toward the targets outlined in the Paris Agreement, which includes a 45 percent reduction in emissions by 2030 and achieving net-zero emissions by 2050.
Dr. Hao Xu, Tencent’s Vice President of Sustainable Social Value and Head of Tencent’s Carbon Neutrality Lab, said: “Technology innovation serves as the driving force to accelerate our progress toward achieving carbon neutrality. CarbonX program is aimed at fostering the growth of these technologies, driving positive impact across society, and laying the groundwork for a more sustainable future.”
Professor Jerry Yan, Chair Professor of the Hong Kong Polytechnic University and Co-chairman of the CarbonX expert committee, said: “To pave the path for a greener economy, we must champion the development of cutting-edge low-carbon technologies. Just as solar and wind power were nurtured in their infancy, emerging solutions like CCUS and tech-based carbon removal demand our early support.”
The program assembled a panel of experts from academia, industries, and the investor community as the jury, and welcomed submissions from diverse participants across three distinct tracks:
CarbonX Lab: Designed to incubate research institutions, universities, or labs that bring in game-changing climate solutionsCarbonX Accelerator: Designed to accelerate the growth of climate-tech startups that exhibit commercialization potentialCarbonX Infrastructure: Designed to support capacity building to facilitate industry developmentThe finalists comprise four projects from the Lab track, six from the Accelerator track, and three from the Infrastructure track. These projects explore innovative solutions, such as using steel slag to capture and store carbon directly from furnace exhaust, converting CO2 into sustainable aviation fuel and valuable chemicals through electrochemical reactions or microorganisms, and employing new approaches to directly capture CO2 from the atmosphere with the hope of slashing the cost to less than US$150 per ton.
Meanwhile, Tencent is also collaborating with Tsinghua University to develop a comprehensive system of Measure, Reporting and Verification (MRV) tools to accurately gauge progress toward decarbonization.
Aside from receiving financial and advisory support, several projects will also have the opportunity to collaborate with industry partners and test their research beyond the laboratory setting.
Building upon the success of the first phase, Tencent is poised to launch the second iteration of CarbonX globally as early as later this year in pursuit of early-stage climate tech innovation.
View original content:https://www.prnewswire.co.uk/news-releases/tencent-announces-winners-of-flagship-carbonx-program-to-combat-climate-change-302153596.html
Artificial Intelligence
NEXCOM Delivers Exceptional Performance in Edge AI Video Analytics
TAIPEI, May 23, 2024 /PRNewswire/ — NEXCOM, a leading supplier of network solutions, published AI and storage performance test results of its NSA 7160R: high-performance Edge server. NSA 7160R is powered by dual Intel® Xeon® Scalable processors for high computing, and enhanced with DDR5 memory, high-bandwidth PCIe Gen5 LAN modules, and high-capacity NVMe storage modules. The test results show the efficiency of the NSA 7160R in processing edge video server workloads and were explained in the accompanying paper.
Edge AI Is the Future
With the rise of smart cities, processing data from cloud to the edge is becoming increasingly critical. Imagine the surge of visual data from ubiquitous security cameras – that information needs real-time analysis right where it’s collected. This is just the tip of the iceberg. As artificial intelligence permeates our lives, certain AI tasks will also need edge computing for efficient, lightning-fast performance. The key is to avoid bottlenecks in the data center by keeping things localized and streamlined.
Your Turnkey Solution Awaits
When it comes to Edge video servers, you need top-notch hardware and software that can handle all the “heavy lifting”. To speed up the total solution bringing up Intel comes in with their Intel® Edge Video Infrastructure (Intel® EVI) reference design. NEXCOM ran a bunch of tests using this design to evaluate its NSA 7160R for essential tasks including storage, image retrieval, and AI features such as inference and feature matching.
After conducting all tests, the results have shown that NSA 7160R meets all performance expectations with outstanding results. For a detailed breakdown of the solution description, test configuration, and results, please refer to the accompanying paper.
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About NEXCOM
Founded in 1992 and headquartered in Taipei, Taiwan, NEXCOM integrates its diverse capabilities and operates six global businesses, including the Network and Communication Solutions (NCS) unit. NCS focuses on the latest network technology and helps to build reliable network infrastructure, by delivering professional design and manufacturing services for customers all over the world. NCS’s network application platform is widely adopted in Cyber Security, Load Balancing, 5G uCPE, SD-WAN, SASE, Edge Computing, OT Security, Storage, NVR, and other network applications for businesses of all sizes.
Video – https://www.youtube.com/watch?v=4WlO8fyWnu4
View original content:https://www.prnewswire.co.uk/news-releases/nexcom-delivers-exceptional-performance-in-edge-ai-video-analytics-302153555.html
Artificial Intelligence
Qiming Venture Partners Promotes Alex Zhou to Managing Partner
SHANGHAI, May 23, 2024 /PRNewswire/ — Qiming Venture Partners, a global-leading venture capital firm, is pleased to announce the promotion of Alex Zhou to Managing Partner.
As a Qiming home-grown Managing Partner, Alex first joined the firm in 2014 as a Vice President and has since emerged as one of the most active investors in frontier technologies, especially in the field of artificial intelligence. Alex will join fellow Managing Partners Duane Kuang, Nisa Leung and William Hu in managing Qiming’s operations.
In the past few years, Alex has actively participated in or led investments in many outstanding technology companies across the artificial intelligence, robotics, semiconductors, new energy vehicles, and software sectors. Notable among these include Roborock, UBTech, Unisound, Biren Technology, ROX Motor, VIEWTRIX Technology, Zhipu AI, Mech-Mind Robotics, Axera, HyperStrong, DeepWay, etc.
“I am deeply grateful for the guidance and trust I received from Qiming over the past 10 years.” Alex said. “We are at the forefront of a new wave of technological revolution. This era will undoubtedly bring about many bold innovators who will shape the future. Together with all the Managing Partners and colleagues at Qiming, I am excited and fully committed to seize the opportunities, embrace any potential challenges, explore new possibilities and build a better Qiming.”
Since its inception 18 years ago, Qiming has always committed to upgrading its institutional capabilities and team development in order to stay ahead in an ever-evolving technological and market landscape. The success achieved in the fields of healthcare, mobile internet and frontier technology is a testament to this strategic approach. Alex’s promotion to the most senior position in the firm demonstrates Qiming’s continued confidence in the future of technology innovation.
About Qiming Venture Partners
Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.
Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, New Horizon Health, Sanyou Medical, AmoyDx, Berry Genomics, SinocellTech, UBTech, Yuanxin Technology, Caidya, Belief BioMed, WeRide, among many others.
View original content:https://www.prnewswire.co.uk/news-releases/qiming-venture-partners-promotes-alex-zhou-to-managing-partner-302153306.html
-
Artificial Intelligence6 days ago
Japan Data Center Market Investment to Reach $14.48 Billion by 2028 – Watch Out Exclusive Insight on Japan & Hong Kong Data Center Market – Arizton
-
Uncategorized5 days ago
Coca-Cola: The future is ‘AI meets human ingenuity’
-
Artificial Intelligence6 days ago
Strava Unveils New Chapter of Accelerated Product Development at Brand’s Flagship Event
-
Artificial Intelligence5 days ago
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
-
Artificial Intelligence6 days ago
Data Center Colocation Market Worth USD 58.4 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.
-
Uncategorized5 days ago
The rise of intelligent automation as a strategic differentiator
-
Artificial Intelligence6 days ago
Arritech Launches QGen Online 2.0 – A Break-Through for Risk Compliance
-
Uncategorized6 days ago
Brinc Acquires Callmi – MENA’s #1 Mentorship Platform